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Abstract Phosphoglycerate dehydrogenase (PHGDH) is
the first enzyme branching from glycolysis in the three-step
serine biosynthetic pathway. Recent evidence has shown
that PHGDH is amplified in human breast cancer and
melanoma and plays a key role in cancer metabolism.
However, PHGDH expression in glioma and a potential
non-metabolic role in tumorigenesis have not been repor-
ted. We analyzed PHGDH levels in specimens from glioma
patients and found that PHGDH, although negative in
normal brain tissues, was highly expressed in astrocytic
tumors and increasingly expressed in more aggressive
cancer types. Inhibition of PHGDH expression in glioma
cells downregulated the expression of VEGF, MMP-2,
CHK2 and cyclin D1 and reduced glioma cell proliferation,
invasion and tumorigenicity in vitro and in vivo. Interest-
ingly, we found that the oncogenic transcription factor
FOXM1 was also downregulated in PHDGH-silenced gli-
oma cells. Using LC/LC MS analysis, we identified
PHGDH as a novel binding partner of FOXM1. PHGDH
interacted with and stabilized FOXM1 at the protein level,
promoting the proliferation, invasion and tumorigenicity of
glioma cells. Our data identified PHGDH as a potential
prognostic marker of glial brain tumors and identified a
non-metabolic role for PHGDH in glioma tumorigenesis,
providing a novel angle of targeting the PHGDH–FOXM1
axis in future brain tumor therapy.
Keywords Phosphoglycerate dehydrogenase  Glioma 
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Introduction
Gliomas are the most common malignant tumor in the
brain, and the overall prognosis for patients with malignant
gliomas is poor. The cumulative 1-year survival rate of
glioma patients is less than 30 % [1]. The most aggressive
type of glioma, glioblastoma, accounts for approximately
50–60 % of all astrocytic tumors and 80 % of all malignant
gliomas and has a median survival of only 15 months [1,
2]. Despite significant advances in neurosurgical tech-
niques and the introduction of novel chemotherapies and
aggressive multimodal treatments, the overall prognosis of
glioma patients remains dismal [3, 4]. Translational and
biological research has revealed that poorly circumscribed
margins, invasion ability, and the uncontrolled prolifera-
tion of gliomas are contributing factors for the aggres-
siveness and high rates of recurrence [5, 6]. Therefore,
understanding the molecular mechanisms of glioma inva-
siveness and proliferation is an urgent challenge in the
development of new therapeutic strategies for this deadly
disease.
The metabolic requirements of cancer cells differ from
their normal counterparts, and altered metabolism is con-
sidered an emerging hallmark of cancer [7, 8]. Among a
Jinlong Liu and Shaolei Guo contributed equally to this study.
Electronic supplementary material The online version of this
article (doi:10.1007/s11060-012-1018-x) contains supplementary
material, which is available to authorized users.
J. Liu  S. Guo  Q. Li  L. Yang  Z. Xia 
Z. Huang  N. Zhang (&)
Department of Neurosurgery, The 1st Affiliated Hospital of Sun
Yat-sen University, No 58, Zhongshan 2 Road, Guangzhou,
Guangdong Province 510080, People’s Republic of China
e-mail: zhangxiaonu@gmail.com
L. Zhang
Laboratory Center of Surgery, The 1st Affiliated Hospital of Sun
Yat-sen University, Guangzhou, Guangdong Province 510080,
People’s Republic of China
123
J Neurooncol (2013) 111:245–255
DOI 10.1007/s11060-012-1018-x
number of metabolic enzymes, one key enzyme for serine
biosynthesis, PHGDH, has been reported in recent cancer
biology studies [9]. Evidence has shown that PHGDH is
amplified or overexpressed in a subset of melanoma and
breast cancers [10, 11]. Depletion of PHGDH strongly
inhibited the proliferation of a panel of breast cancer cells
with amplified or overexpressed PHGDH [10]. However,
the expression patterns of PHGDH in glioma and its
molecular functions (aside from being a metabolic enzyme)
have not yet been reported.
In this study, we showed that PHGDH was robustly
expressed in a large proportion of astrocytomas, and its
expression levels increased with tumor grade. Mechanistic
investigations revealed that deprivation of PHGDH in gli-
oma cells impaired proliferation and invasiveness. In nude
mice injected with stable, PHGDH-silenced glioma cells, the
overall survival was dramatically prolonged compared with
the mice injected with wild-type cells. Furthermore, we
identified PHGDH as a novel binding partner of FOXM1.
This interaction stabilized FOXM1 protein levels and
sequentially induced the expression of a series of oncogenes,
such as MMP-2, VEGF, Chk2 and cyclin D1, which suggests
that in addition to metabolic functions, PHGDH may have
other biological roles in glioma tumorigenesis.
Materials and methods
Patient information and tissue specimens
A total of 132 paraffin-embedded glioblastoma samples
were histopathologically and clinically diagnosed at our
department from 2000 to 2006. Five paired patient sam-
ples, including tumor and tumor-adjacent tissues, were
collected during surgery. Prior patient consent and
approval from the Institutional Research Ethics Committee
were obtained for the use of these clinical materials for
research purposes.
Cell lines and reagents
The glioma cells U87, U251, A172 and U373 were kindly
provided by Dr. Suyun Huang, MD Anderson Cancer
Center, Houston, TX. Human embryonic kidney 293T cells
were obtained from the American Type Culture Collection,
and normal human astrocyte cells were purchased from
Lonza. The glioma cell lines and 293T cells were cultured
in DMEM supplemented with 10 % fetal bovine serum
(Invitrogen). The normal human astrocyte cells were
maintained in Astrocyte Basal Medium (Lonza) plus AGM
SingleQuots. Antibodies against PHGDH (sc-100317),
FOXM1 (sc-500), MMP-2 (sc-13594), VEGF (sc-152),
chk2 (sc-5278), and cyclin D1 (sc-717) were purchased
from Santa Cruz Biotechnology; the antibody against actin
was obtained from Sigma. The shRNA sequences targeting
PHGDH were as follows: sh-PHGDH-1, CCGGAGGTG
ATAACACAGGGAACATCTCGAGATGTTCCCTGTGTT
ATCACCTTTTTT; and sh-PHGDH-2, CCGGCTTAGCA
AAGAGGAGCTGATACTCGAGTATCAGCTCCTCTTTG
CTAAGTTTTT. The control shRNA sequence targeted GFP.
The fluorescent secondary antibodies Alexa Fluor 488 and
Alexa Fluor 596 were from Invitrogen.
Cell transfection and viral infection
To introduce short hairpin RNAs into the glioma cells, we
used the PRNATU6.2 Lenti vector to generate viruses.
Viral infections were serially performed, and stable cell
lines expressing PHGDH RNAi(s) were selected using
0.5 lg/mL puromycin.
Flow cytometry
The cells were harvested and fixed in ice cold 75 % ethanol
before staining with propidium iodide (Sigma, 0.45 mg/mL),
RNase (Sigma, 0.45 mg/mL), and 0.045 % Tween-20
(Sigma). The resuspended cells were analyzed for DNA
content using a fluorescence-activated cell sorter (FACS;
Vantage), and the data were processed using FACS Cell
Quest software (Becton–Dickinson).
Colony formation assays
Glioma cells carrying PHGDH or control shRNA were
dissociated to single cell suspension in 0.6 % top agar
medium and plated in triplicate in 60-mm dishes (300 cells
per dish) that had been pre-coated with 1.2 % agar med-
ium. The emergent colonies were stained with crystal
violet 14 days later and counted.
Immunohistochemical analyses
Immunohistochemical analyses were performed by staining
tissue sections from paraffin-embedded specimens with an
anti-PHGDH antibody. Nonspecific immunoglobulin (IgG)
was used as a negative control. We quantitatively scored
tissue sections according to the percentage of positive cells
and staining intensity as previously described [12].
Immunofluorescence staining
The cells were fixed with 4 % paraformaldehyde, perme-
abilized with phosphate-buffered saline (PBS) containing
0.1 % Triton X-100, and blocked with 1 % bovine serum
albumin. Immunostaining was performed using the appro-
priate primary antibodies and stained with 40,6-diamidino-
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2-phenylindole, anti-rabbit IgG conjugated with Alexa
Fluor 488 or anti-mouse IgG conjugated with Alexa Fluor
596. The images were acquired using a scanning confocal
microscope (Olympus FluoView FV1000).
Real-time RT-PCR
Total RNA from cultured cells and frozen glioma tissues
was extracted using TRIzol reagent (Invitrogen). Real-time
RT-PCR assays were performed as described previously
[12]. Each sample was analyzed in triplicate for the target
gene and internal control.
Western blotting, immunoprecipitation and MS
A Western blot analysis of cell lysates was performed with
the antibodies previously described. The membranes were
stripped and re-probed with an anti-beta-actin antibody as a
loading control. For immunoprecipitation, the cells were
lysed with sample buffer containing 62.5 mmol/L Tris–
HCl (pH 6.8) and 10 % glycerol. Equal amounts of protein
were mixed with antibodies and then incubated while being
rotated overnight, followed by an agarose A/G bead (Mil-
lipore) addition. For MS analysis, the immunoprecipitates
were separated on an SDS-PAGE gel, and various protein
bands were collected, tryptically digested, and subjected to
LC/LC MS analysis.
Cell invasion assays
Cell invasion and migration assays were performed using a
transwell system that incorporated a polycarbonate filter
membrane (Corning, NY). To assess invasion, the filters
were pre-coated with 10 lg of Matrigel (BD Biosciences,
Franklin Lakes, NJ). A pretreated cell suspension (105) in
serum-free culture media was added to the inserts, and each
insert was placed in the lower chamber filled with culture
media containing 10 % FBS. After a 24-h incubation, the
filters were fixed and stained with a 0.1 % crystal violet
solution for 10 min. Five fields of adherent cells in each
well were randomly imaged and counted.
Intracranial tumor assay
Male, athymic, BALB/c nude mice were purchased from the
Animal Center of Sun Yat-sen University. Glioma cells were
intracranially injected into the nude mice as previously
described. The animals were euthanized when they were
moribund, and the remaining animals were euthanized
60 days after glioma cell injection. Each mouse brain was
harvested, and tumor formation was determined by histo-
logical analysis. To analysis the tumor size and invasion,
each of the tumor size was determined by three of the brain
sections in which the tumor has the largest diameter. The
invasion was counted when the invaded lesion is larger than
0.32 mm in 1 dimension of the slides. (The brain diameter of
mouse/human is 12 mm/150 mm, and the clinical detectable
invaded tumor on MRI is 5 mm. For mouse, the diameter
should be 0.32 mm/12 mm = 0.03 compare with human
5 mm/150 mm = 0.03). The quantitative data of the in vivo
tumor formation and invasion assay was shown in Fig. 5 and
Supplementary Tables 3 and 4.
Statistical analyses
Statistical analyses were performed using the SPSS soft-
ware program (SPSS Standard version 13.0, SPSS Inc,
Chicago, IL). The association between PHGDH expression
and clinicopathologic grade was analyzed using Spearman
rank test. The statistical significance of the correlation
between PHGDH expression and disease-specific survival
was estimated by the log-rank test. Evaluation of signifi-
cant differences for in vitro data was determined using
Student’s t test (two-tailed), one-factor of variance
(ANOVA) analysis, two-factor of variance (ANOVA)
analysis or Wilcoxon signed-rank test; and for in vivo data
using the Mann–Whitney U test. Results are expressed as
mean ± SD or ± SE from 3 independent experiments. A
significance level set at p \ 0.05.
Results
PHGDH was overexpressed in glioma samples
at both the mRNA and protein levels
A total of 132 paraffin-embedded glioma specimens were
obtained from patients who had undergone operations and
were pathologically diagnosed in our department from
2001 to 2006 (the patient data are summarized in Supple-
mentary Table 1); 10 normal brain tissue samples were
also obtained. We detected PHGDH expression in these
samples using a PHGDH-specific antibody. The positivity
of PHGDH staining was increased in the more aggressive
tumors, whereas the normal brain samples were PHGDH
negative (Fig. 1a). We defined a Scoring Index (SI) for
IHC staining samples: 0 (no positive tumor cells), 1
(\10 % positive tumor cells), 2 (10–50 % positive tumor
cells), and 3 ([50 % positive tumor cells). The intensity of
staining was graded according to the following criteria: 0
(no staining); 1 (weak staining = light yellow), 2 (mod-
erate staining = yellow brown), and 3 (strong stain-
ing = brown). The staining index (SI) was calculated as
staining intensity score x proportion of positive tumor cells
(0, 1, 2, 3, 4, 6, 9). Cutoff values to define the high- and
low-expression of PHGDH were chosen on the basis of a
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measurement of heterogeneity with the log-rank test sta-
tistic with respect to overall survival. Because univariate
analysis demonstrated that the Cutoff value of 3 led to the
highest significant difference with respect to overall sur-
vival in glioma between the respectively defined subgroup,
an SI score [3 was taken to define tumors as high
expression, and SI \ 3 to define tumors as low expression
of PHGDH. In the 132 tumor samples, 90 exhibited high
PHGDH expression levels (68.2 %), and 42 exhibited low
expression levels (31.8 %). In the statistical analyses, we
determined that PHGDH expression levels highly corre-
lated with the clinicopathological grade of the glioma
samples (Fig. 1b; Supplementary Table 1; p \ 0.0001).
Next, we used Q-PCR to detect PHGDH mRNA expression
levels in detect the PHGDH mRNA expression of 40 gli-
oma tissues (10 grade I astrocytomas, 10 grade II astro-
cytomas, 10 anaplastic astrocytomas and 10 glioblastomas)
and 10 normal brain tissues. As shown in Fig. 1c, the
higher grade tumors showed elevated PHGDH mRNA
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Fig. 1 PHGDH was
overexpressed in glioma
samples at both the mRNA and
protein levels. a Representing
photes of parafin-embedded
specimens of 132 primary
astrocytoma specimens
including WHO grade I–IV and
10 normal brain tissues stained
by immunohidtochemistry using
anti-PHGDH antibody. IgG
were used as negative control.
Amplifications are 2009.
b Scoring of IHC staining
samples. c Quantification PCR
were used to detect the PHGDH
mRNA expression of 40 glioma
tissues (10 grade I astrocytomas,
10 grade II astrocytomas, 10
anaplastic astrocytomas and 10
glioblastomas) and 10 normal
brain tissues. The expression
level was normalized to
GAPDH (log)
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the expression levels in GBMs compared with the normal
brain. These data indicated that PHGDH was overexpres-
sed in glioma, and its expression correlated with the glioma
WHO grades.
PHGDH as a prognostic marker for glioma
To exclude the possibility that high PHGDH expression
levels were due to cell types other than the astrocytomas,
we analyzed PHGDH mRNA and protein expression levels
in glioma cell lines and compared them with normal human
astrocytes (NHA). As shown in Fig. 2a, b, PHGDH mRNA
and protein was barely detectable in the NHA, whereas
PHGDH mRNA and protein expression levels increased to
different levels in the glioma cell lines. Because of the
complexities of the genetic variation of these cell lines, we
tested 5 paired clinical samples to confirm our findings. Not
surprisingly, PHGDH mRNA and protein expression levels
were elevated in all 5 paired samples (Fig. 2c, d). Kaplan–
Meier curves indicated that in WHO grade I and II glioma
patients, the 5-year survival was 82.3 % in the low-
PHGDH expression group compared with 64.5 % in the
high-PHGDH expression group (p \ 0.001). In the WHO
grade III and IV groups, the 5-year survival was 43.3 % in
the low-PHGDH expression group compared with 18.5 %
in the high-PHGDH expression group (p \ 0.001). These
data suggest that PHGDH is a prognostic marker for
patients with glioma (Supplementary Table 2).
Silencing of PHGDH attenuated glioma cell
proliferation and invasion
Recent evidence has shown that serine metabolism plays a
pivotal role in human malignancy [13, 14]. As a key enzyme
in serine de novo synthesis, inhibition of PHGDH inhibits
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Fig. 2 PHGDH as a prognostic
marker for glioma. a Expression
analysis of PHGDH protein in
normal human astrocytes and
astrocytoma cell lines by
Western blotting. b Expression
analysis of PHGDH mRNA in
normal human astrocytes and
astrocytoma cell lines by
Q-PCR. c Differential
expression of PHGDH protein
in 5 primary astrocytoma
specimens and their paired
tumor adjacent tissues were
detected by Western blotting.
d Differential expression of
PHGDH mRNA in the same 5
paired specimens in Fig. 2c was
detected by Real-Time RT-
PCR. Expression was
normalized to GAPDH and SD
was from 3 independent
experiments. e Kaplan–Meier
curves with univariate analyses
(log rank) for low PHGDH
expression versus high PHGDH
expression in WHO I-II glioma
patients and WHO III-IV
glioma patients
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breast cancer and menaloma [10, 11, 15]. To test whether
this effect also exists in glioma cells, we established U87
and U251 cells with PHGDH stably silenced by 2 inde-
pendent shRNAs referred to as PHGDH-1 and PHGDH-2.
As shown in Fig. 3a, compared with the negative control,
PHGDH-1 and PHGDH-2 significantly downregulated
PHGDH expression levels in both cell lines. We next
detected several oncogenes that were closely related to
tumor proliferation and invasion in PHGDH-silenced U87
and U251 cells. The PHGDH shRNA dramatically reduced
the expression levels of MMP-2 and VEGF, which are
oncogenes important for tumor invasion and angiogenesis.
Chk2 and cyclin D1, hallmarks of tumor proliferation, were
also downregulated after PHGDH knockdown (Fig. 3a).
Next, we examined whether PHGDH inhibition could















































































Fig. 3 Silencing of PHGDH attenuated glioma cell proliferation and
invasion. a Expression of series proliferation and invasion markers
after PHGDH stable silencing in U87 and U251 cells was analyzed by
western blot. b Upper, Photographs of transwell invasion assay of
U87 and U251 cells that express shRNAs for control or PHGDH.
Lower, the transwell invasion assay efficiency of the cells in a. Values
are mean ± SD for triplicate samples and a two-way ANOVA was
used to test the significance (p \ 0.0001). c U87 and U251 cells that
express shRNAs for control or PHGDH were subjected to flow
cytometry assay. Values are mean ± SD for triplicate samples and a
two-way ANOVA was used to test the significance (p \ 0.0001). d
Upper, photographs of soft agar colony formation of U87 and U251
cells that express shRNAs for control or PHGDH. Magnifications are
2009. Lower, the secondary neurosphereformation efficiency
(spheres/cells plated) of the cells in A. Values are mean ± SD for
triplicate samples and a Wilconxon test was used to test the
significance (p \ 0.05)
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shown in Fig. 3b, PHGDH knockdown produced a signifi-
cant reduction in the number of invasive cells. Compared
with the control group, the number of invasive cells was
reduced to 61.174 ± 1.25 % (PHGDH-1) and 63.86 ±
1.87 % (PHGDH-2) in U251 cells and 52.73 ± 0.96 %
(PHGDH-1) and 51.43 ± 1.05 % (PHGDH-2) in U87 cells.
To test the PHGDH silencing effects on proliferation, we
analyzed the cell cycle distribution and tumorigenicity
using flow cytometry and colony formation assays,
respectively. After PHGDH inhibition, the U87 and U251
glioma cells exhibited a massive G2 arrest compared with
the control cells. The G2-arrested cells increased to
33.9 ± 6.78 % (PHGDH-1) and 36.7 ± 6.22 % (PHGDH-
2) in U87 cells and 32.20 ± 5.34 % (PHGDH-1) and
37.10 ± 4.10 % (PHGDH-2) in U251 cells, compare with
14.40 ± 3.57 % and 12.60 % ± 2.13 % in control U87 and
U251 cells (Fig. 3c). PHGDH-silenced U87 and U251 cells
both showed impaired tumorigenicity, as indicated by the
observation that their colony formation ability was signifi-
cantly decreased compared with the control groups
(Fig. 3d). These results suggested that PHGDH contributed
to glioma cell invasion and proliferation.
PHGDH interacted with and stabilized FOXM1
in glioma cells
Interestingly, FOXM1 expression levels were also found to
be decreased when PHGDH was silenced (Fig. 3a).
FOXM1 is a well-known oncogene that induces cell pro-
liferation, invasion and tumorigenecity [16–18]. In addi-
tion, key regulators of the cell cycle, cyclin D1 and chk2,
are both direct transcriptional targets of FOXM1 [19, 20]
We found that the mRNA levels of FOXM1 did not change
when PHGDH was silenced (Fig. 4a). Using LC/LC MS,
we identified PHGDH as a novel binding partner of
FOXM1 (Supplementary Fig. 1). This result was confirmed
through endogenous co-immunoprecipitation in U87 and
U251 cells (Fig. 4b). To further validate this result, we
performed immunofluorescence staining in U251 cell. As
shown in Fig. 4c, both FOXM1 and PHGDH were strongly
expressed in U251 cells, and these two proteins showed
significant co-localization in the cytoplasmic but not
nuclear region. Deletion fragments co-immunoprecipita-
tion studies indicated that PHGDH interacts with the
N-terminal region of FOXM1 (Fig. 4d). As N-terminal
region of FOXM1 is known to induce FOXM1 degradation
[21], we hypothesized that PHGDH could stabilize
FOXM1 and protect it from degradation. Thus, we com-
pared the degradation pattern of FOXM1 in PHGDH-
knocked down U251 cells and control cells with cyclo-
heximide treatment. In control cells, the FOXM1 density
remained at 62.23 ± 11.64 % compared with 9.65 and
3.0 % in the PHGDH-silenced group after 12 h. In
addition, the FOXM1 density curves showed faster degra-
dation in PHGDH-silenced cells (Fig. 4e). The protesome
inhibitor MG132 could reverse the effects of PHGDH
silencing induced FOXM1 down regulation; and when
PHGDH silenced by specific siRNA the ubiqutin conju-
gated FOXM1 increased dramatically compare with con-
trol group. From these data, we concluded that PHGDH
could stabilize FOXM1 protein from degradation in glioma
cells.
PHGDH silencing inhibited glioma tumorigenicity
in nude mice
Finally, we tested the tumorigenicity after PHGDH silenc-
ing in nude mice. As previously described [22], we injected
the control and PHGDH-silenced U87 and U251 cells into
the brains of nude mice. In the control group, both cell lines
resulted in the death of all 5 mice within 50 days, while the
si-PHGDH-1 and si-PHGDH-2 groups showed a prolonged
survival time (Log-rank tests of overall survival
p \ 0.0001). The mouse brain section staining confirmed
that both the tumor size and invasion were dramatically
inhibited after PHGDH silencing (Supplementary Tables 3
and 4) and a two-way ANOVA analysis of tumor diameter
or invasion lesion numbers with respect to cell line (U87
versus U251) and shRNA expression was shown the results
were significant (Fig. 5a, b, c).
Discussion
Cancer cells are known to import and consume increased
amounts of glucose compared with normal cells [23]. In
brain tumors, the best evidence that metabolic enzymes
play a causative role comes from the discovery of the IDH1
and IDH2 mutations [24]. More than 70 % of Stage II–III
astrocytoma or oligodendroglioma tumors have mutations
in either IDH1 or IDH2 [25]. PHGDH, the gene encoding
the enzyme that controls the flux from glycolysis into the
serine biosynthesis pathway, is a candidate oncogene. In
breast cancer, elevated PHGDH levels are more frequently
found in estrogen receptor-negative and basal-like tumors.
RNAi-mediated depletion of PHGDH has little effect on
the viability of untransformed breast epithelial cells or
breast cancer cells without PHGDH amplification/over-
expression [10]. Melanoma, however, with 39 % of sam-
ples exhibiting some form of copy number gain, had the
highest frequency of PHGDH amplification among tumor
types that were analyzed [11]. Consistent with the results in
breast cancer, knockdown of PHGDH inhibited the growth
of melanoma cell lines that harbored the PHGDH ampli-
fication but had no effect on lines lacking the amplification
[11]. Based on these results, PHGDH may be an ideal drug





























Hrs post CHX 0 4 8 12 0 4 8 12
FOXM1
β−actin

















































- +         -
HA-ub
- +         +










Fig. 4 PHGDH interacts with and stabilize FOXM1 in glioma cells.
a Expression of FOXM1 mRNA in U87 and U251 cells that express
shRNAs for control or PHGDH was detected by Real-Time RT-PCR.
Expression was normalized to GAPDH and SD was from 3
independent experiments (p = 0.1325). b Endogenous binding of
PHGDH and FOXM1 were detected by using anti-PHGDH or anti-
FOXM1 antibodies, respectively, in U87 and U251 cells. c U251 cells
were plated in chambers precoated with poly-L-ornithine and
fibronectin before stained with anti-FOXM1 and anti-PHGDH
antibodies. Images were acquired using a scanning confocal micro-
scope (Olympus FluoView FV1000). Scale bar for 20uM. d Flag-
tagged FOXM1 fragments as indicated were transfected into U87
cells. 48 h post transfection, the co-IP were performed by using anti-
FLAG antibody. e U251 cells that express shRNA for control or
PHGDH were treated with cyclohexmide (50 lM) for 24 h before
subjected to western blot analysis. The densitometry was acquired by
Beckman Appraise, Beckman Instruments (p \ 0.0001 in two way
ANOVA). f Upper, control siRNA and PHGDH-2 siRNA were
transfected into U87 glioma cells and 20 lM of MG132 were added
as indicated 24 h post transfection. Total protein was analyzed 48 h
post transfection by western blot. Lower, Flag-tagged FOXM1, HA-
tagged Ubqutin and PHGDH-2 siRNA were co-transfected into U87
glioma cells as indicated. 48 h post transfection, co-IP experiments
were done by using anti-Flag antibody
252 J Neurooncol (2013) 111:245–255
123
target for cancer therapy. However, the expression of
PHGDH in glioma and its roles in addition to the Warburg
effect has not yet been demonstrated.
Genome-wide gene expression profiling has indepen-
dently and consistently identified FOXM1 as one of the
most commonly upregulated genes in human solid tumors
[26, 27]. Depletion of FOXM1 in glioma cells resulted in a
reduction in cell proliferation and anchorage-independent
colony formation on soft agar. Furthermore, FOXM1





































































Fig. 5 PHGDH silencing inhibited glioma tumorigenicity in nude mice.
a 1*106 U87 and U251 glioma cells that express shRNA for control or
PHGDH were injected intracranially into nude mice as described
previously. Brains were harvested when the animal were moribund; the
remaining animals were killed 60 days after glioma-cell injection. Each
mouse’s brain was fixed in 4 % formaldehyde, and embedded in paraffin.
Tumor formation was determined by histologic analysis of H&E-stained
sections. Magnification, 1009. b Statistical analysis of tumor size and
invasion in intracranial tumor assay, a two-way ANOVA analysis of
tumor diameter or invasion lesion numbers with respect to cell line (U87
versus U251) and shRNA expression (GFP, si-PHGDH-1, si-PHGDH-2,
p \ 0.0001). c Kaplan–Meier curves with univariate analyses (log rank)
of nude mice Intracranial Tumor Assay, p \ 0.0001
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the cell cycle proteins cyclin A2, cyclin B1, and Cdc25
phosphatases and increased expression levels of the cell
cycle inhibitors p21Waf1/Cip1 and p27Kip1 [28]. Other
evidence has shown that suppression of FOXM1 leads to a
reduction in MMP-2 and MMP-9 expression levels in
pancreatic cancer cells, which is associated with an overall
decrease in cancer cell migration, invasion and angiogen-
esis [29]. Reports have shown that FOXM1 is transcrip-
tionally regulated by Gli1 in basal cell carcinomas [30];
however, whether FOXM1 is regulated at the protein level
has not been reported.
To explore PHGDH expression in gliomas, we per-
formed immunohistochemical analysis on 132 paraffin-
embedded glioma specimens ranging from WHO grade I to
grade IV. We found that PHGDH expression levels cor-
related with the tumor grade, whereas normal brains
showed no detectable PHGDH staining. The results were
consistent with the PHGDH expression pattern in mela-
noma and breast cancer. Moreover, we identified PHGDH
as a potential prognostic marker for glioma patient cumu-
lative survival. Further studies showed that PHGDH
interacts with N-terminal of FOXM1, stabilized FOXM1
from ubiqutintion induced protesome degradation in gli-
oma cells, suggesting that PHGDH may be a regulator of
FOXM1, and that PHGDH has additional biological func-
tions in addition to those as a metabolic enzyme. Further
work will be focus on how PHGDH affects the FOXM1
N-terminal induced degradation process. Recent reports
have shown that another metabolic enzyme, embryonic
pyruvate kinase M2, can induce beta-catenin translocation
upon EGFR activation, which is another example of a
metabolic enzyme playing a non-metabolic role in tumor-
igencity [31]. We inferred that PHGDH is a direct upstream
regulator of FOXM1, and targeting PHGDH not only
inhibited the aberrant metabolism of tumor cells but also
depleted FOXM1 expression, thus attenuating tumor pro-
liferation and invasion.
In conclusion, we report that PHGDH is a novel prog-
nostic marker in glioma patients. Inhibition of PHGDH in
glioma cells significantly decreased cell proliferation,
invasion and tumorigenicity. Mechanistic studies revealed
that PHGDH could interact with FOXM1 and stabilize it at
the protein level. The PHGDH-FOXM1 axis may be an
ideal drug target for future brain tumor treatments.
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